Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Cancer Cell. 2021 Dec 30;40(1):53–69.e9. doi: 10.1016/j.ccell.2021.12.005

Figure 4. GPC2-CAR T cells with CD28 TM domains control patient derived xenografts and CD28 outperforms 41BB costimulatory endodomains.

Figure 4.

A) Experimental in vivo setup testing GPC2.19-CAR T cells in COG-N-421x PDX models bearing moderate size tumor burden (MOD: range mean TU vol 0.22–0.24 cm3) or high size tumor burden (HI: range mean TU vol 0.65–0.78 cm3).

B-C) Tumor volume (B) after treatment and C) Kaplan-Meier survival analysis of the MOD tumor burden arm. Mice in the GPC2.19.28TM.41BBz group were euthanized due to clinical signs of GvHD by day 32, as was one mouse in the FMC63.CTRL group on d35 and were censored from the analysis.

D-E) Tumor volume (B) after treatment and E) Kaplan-Meier survival analysis of the HI tumor burden arm. Three mice in the GPC2.19.28TM.41BBz group were euthanized due to clinical signs of GvHD by d32 and were censored from the analysis. Endpoints were defined maximum tumor burden >2 cm3 volume or signs of GVHD.

Statistics in B and D represent two-way RM-ANOVA (**** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05), ns = p > 0.05).